Navigation Links
Omni Bio Pharmaceutical Intends to Expand Type 1 Diabetes Trial to 50 Patients
Date:2/28/2011

upon receipt of required regulatory approval and adequate financing.

Dr. Charles Dinarello, Omni Bio's Director of Medical Affairs and Chief Scientific Officer commented, "Whereas we are well into the infusion stage on our first human clinical trial of Alpha-1 antitrypsin ("AAT") in Type 1 diabetes, it is essential that we establish the foundation for pursuing the commercialization of other significant areas of our intellectual property.  Over the past six months, we have initiated discussions and provided data to leading researchers and international investigators related to our intellectual property, and are pleased to advise our shareholders that we are planning substantive programs to investigate and prove AAT's effectiveness in treating additional disease classifications."  Dr. Crapo further added, "Dr. Dinarello's own work and that of his collaborators in the fields of transplantation and GVHD are widely recognized and offer Omni Bio potential new and large markets for AAT alternative use.  While in Europe over the past several months, Charles has devoted considerable time in building key strategic relationships for Omni Bio with internationally-renowned scientists."

There is no assurance that the letters of intent will lead to the commencement of actual trials or that Omni Bio will receive regulatory approvals or be able to raise additional capital on acceptable terms or at all.

Letters of intent for human clinical trials

  • The treatment of Graft vs. Host Disease in bone marrow transplant patients.  Proposed Trial Site:  University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.  Principal Investigator:  Pavan Reddy, MD, Associate Professor of Internal Medicine, Co-Director, BMT Leukemia/Lymphoma.
  • Two separate human clinical trials for the treatment of transplant rejection in kidney transplant recipients.  Proposed Trial Site:  Radboud University, Nijmegen M
    '/>"/>

  • SOURCE Omni Bio Pharmaceutical, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/29/2015)... June 30, 2015 Mordor Intelligence presents ... Primary Packaging Material (Plastic, Glass, Paper, Metal) - ByType of ... Pouches, Syringes, Tubes, Vials, Sachets) - By Geographical Region ( ... Asia Pacific , Latin America ... Africa ) - discussing Industry Value Chain Analysis, ...
    (Date:6/29/2015)... June 29, 2015  New guidelines released today ... Association give hope for better outcomes to the ... acute ischemic stroke each year. Stryker,s Trevo ® ... used in the clinical trials that provided data ... guidelines strongly recommend endovascular therapy with stent retrievers ...
    (Date:6/29/2015)... Minn. , June 29, 2015 EnteroMedics ... of devices that use neuroblocking technology to treat obesity, ... it has commenced an underwritten public offering of units. ... stock, Series A warrants to purchase common stock and ... purchase of units in the offering would result in ...
    Breaking Medicine Technology:Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 2Global Pharmaceutical Packaging Market - North America and Europe Expected to Lead Followed by the Asia Pacific Market 3New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 3
    ... June 21, 2011 Enox Biopharma, Inc. CEO, John C. ... Innovation Conference on Wednesday, June 22 at 12:15 AM EST. ... in Boston. The IN3 East meeting, hosted ... The meeting is designed to provide exposure and constructive interaction ...
    ... MOUNT LAUREL, N.J., June 21, 2011 ImpactRx, ... on physician prescribing behavior announced that Kjell Nygren, ... Analytical Services.  Kjell will strengthen the company,s position ... address clients, needs for better understanding the effectiveness ...
    Cached Medicine Technology:Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference 2ImpactRx Names Kjell Nygren Vice President, Analytical Services 2
    (Date:6/30/2015)... ... 30, 2015 , ... Dr. Sammy Masri of Masri Sports Medicine &Wellness, NJ ... the diagnosis and treatment of non-surgical sports and other musculoskeletal injuries for both adults ... athletics and use exercise to stay healthy and active. Dr. Masri seeks to provide ...
    (Date:6/30/2015)... ... 2015 , ... MJH Associates today welcomed Jim ... & Analytics , a consultative healthcare market research practice that is part of ... offers quantitative and qualitative, custom and multi-client primary market research services to support ...
    (Date:6/30/2015)... ... June 30, 2015 , ... America’s oldest cancer ... access to cancer prevention, screening and care for the people of Nigeria. Roswell ... that will see Roswell Park faculty providing clinical consultations to assist LCC oncologists, ...
    (Date:6/30/2015)... ... June 30, 2015 , ... New Energy Works Timberframers ... 7th and 11th 2015. Timber frame post and beam raisings offer a chance to ... a timber frame is an important and exciting event – it is ...
    (Date:6/30/2015)... Cruz, CA (PRWEB) , ... June 30, 2015 ... ... product is now the official ready-to-drink sponsor of two leading organizations dedicated to ... Some Assembly Required (SAR). , I AM ADAPTIVE™ is now the official charity ...
    Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 2Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 3Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 4Health News:LifeAID Beverage Company Partners With The Adaptive Movement 2Health News:LifeAID Beverage Company Partners With The Adaptive Movement 3
    ... they need, but sickest still going without, study finds , , ... benefit has resulted in some improvements for seniors but no ... report finds that Medicare beneficiaries are less likely to forego ... the sickest patients are still skipping meds due to burdensome ...
    ... researchers have peered deeply at the atomic level into the ... disease thought to cause stroke and dementia. , The study ... key to the formation of plaques in blood vessels in ... his colleagues report their results this week in the online ...
    ... part of ,Muslims Care, campaign, WASHINGTON, April 22 ... by a prominent national Islamic civil rights and,advocacy group ... in,the Susan G. Komen National Race for the Cure., ... American-Islamic,Relations, will carry its own "Muslims Care" banner and ...
    ... GAINESVILLE, Fla. Spreading rumors and gossiping may not ... of this social type of bullying could linger into ... , In a study of 210 college students, ... relational victimization in adolescence and depression and anxiety in ...
    ... Perot Systems,Corporation (NYSE: PER ) and ... which Perot Systems will implement advanced technology,solutions to ... this,agreement, Perot Systems will help SCA improve support ... outpatient surgery centers and surgical,hospitals across the country. ...
    ... Resource Guide for Policymakers, Consumers and the Media ... Food, Beverage and Consumer Product,Issues, WASHINGTON, April ... Bisphenol A: A Guide for,Consumers, Policymakers and the ... papers designed to provide current and scientifically accurate,information ...
    Cached Medicine News:Health News:Medicare Prescription Drug Benefit Shows Mixed Results 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 3Health News:First atomic-level look at a protein that causes brain disease 2Health News:Muslim Team to Take Part in D.C. 'Race for the Cure' 2Health News:Social form of bullying linked to depression, anxiety in adults 2Health News:Social form of bullying linked to depression, anxiety in adults 3Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 2Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 3Health News:Grocery Manufacturers Association Releases Science Policy Paper on Bisphenol A 2
    The URCA (Uric acid) method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of uric acid in serum, plasma and urine....
    For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
    The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
    For the quantitative in vitro determination of Triglycerides in serum and plasma....
    Medicine Products: